Verification of Dose Distribution in Carbon Ion Radiation Therapy for Stage I Lung Cancer

被引:18
|
作者
Irie, Daisuke [1 ]
Saitoh, Jun-ichi [1 ]
Shirai, Katsuyuki [1 ]
Abe, Takanori [1 ]
Kubota, Yoshiki [1 ]
Sakai, Makoto [1 ]
Noda, Shin-ei [1 ]
Ohno, Tatsuya [1 ]
Nakano, Takashi [1 ]
机构
[1] Gunma Univ, Heavy Ion Med Ctr, Maebashi, Gunma, Japan
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2016年 / 96卷 / 05期
关键词
PROTON THERAPY; CLINICAL-EXPERIENCES; RESPIRATORY MOTION; PROSTATE-CANCER; RADIOTHERAPY; JAPAN; PLANS;
D O I
10.1016/j.ijrobp.2016.09.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate robustness of dose distribution of carbon-ion radiation therapy (C-ion RT) in non-small cell lung cancer (NSCLC) and to identify factors affecting the dose distribution by simulated dose distribution. Methods and Materials: Eighty irradiation fields for delivery of C-ion RT were analyzed in 20 patients with stage I NSCLC. Computed tomography images were obtained twice before treatment initiation. Simulated dose distribution was reconstructed on computed tomography for confirmation under the same settings as actual treatment with respiratory gating and bony structure matching. Dose-volume histogram parameters, such as %D95 (percentage of D95 relative to the prescribed dose), were calculated. Patients with any field for which the %D95 of gross tumor volume (GTV) was below 90% were classified as unacceptable for treatment, and the optimal target margin for such cases was examined. Results: Five patients with a total of 8 fields (10% of total number of fields analyzed) were classified as unacceptable according to %D95 of GTV, although most patients showed no remarkable change in the dose-volume histogram parameters. Receiver operating characteristic curve analysis showed that tumor displacement and change in water-equivalent pathlength were significant predictive factors of unacceptable cases (P<.001 and P=.002, respectively). The main cause of degradation of the dose distribution was tumor displacement in 7 of the 8 unacceptable fields. A 6-mm planning target volume margin ensured a GTV %D95 of >90%, except in 1 extremely unacceptable field. Conclusions: According to this simulation analysis of C-ion RT for stage I NSCLC, a few fields were reported as unacceptable and required resetting of body position and reconfirmation. In addition, tumor displacement and change in water-equivalent
引用
收藏
页码:1117 / 1123
页数:7
相关论文
共 50 条
  • [1] Carbon Ion Radiation Therapy for Stage I Breast Cancer
    Karasawa, K.
    Omatsu, T.
    Wakatsuki, M.
    Shiba, S.
    Fukuda, S.
    Kamada, T.
    Yamamoto, N.
    Ishikawa, T.
    Arakawa, A.
    Saito, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E7 - E7
  • [2] Carbon Ion Radiation Therapy for Stage I Breast Cancer
    Karasawa, K.
    Omatsu, T.
    Harada, M.
    Koba, Y.
    Fukuda, S.
    Kamada, T.
    Saito, M.
    Kohno, N.
    Yamamoto, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S229 - S229
  • [3] High-Dose Proton Therapy and Carbon-Ion Therapy for Stage I Nonsmall Cell Lung Cancer
    Iwata, Hiromitsu
    Murakami, Masao
    Demizu, Yusuke
    Miyawaki, Daisuke
    Terashima, Kazuki
    Niwa, Yasue
    Mima, Masayuki
    Akagi, Takashi
    Hishikawa, Yoshio
    Shibamoto, Yuta
    CANCER, 2010, 116 (10) : 2476 - 2485
  • [4] The relative biological effectiveness of carbon ion radiation therapy for early stage lung cancer
    Jeong, Jeho
    Taasti, Vicki T.
    Jackson, Andrew
    Deasy, Joseph O.
    RADIOTHERAPY AND ONCOLOGY, 2020, 153 : 265 - 271
  • [5] Dose Escalated Radiation Therapy for Advanced Stage Lung Cancer
    Shusharina, N.
    Sharp, G.
    Niemierko, A.
    Choi, N.
    MEDICAL PHYSICS, 2017, 44 (06) : 3308 - 3308
  • [6] Surgery Versus Radiation Therapy in Stage I Lung Cancer
    Mokhles, Sahar
    Takkenberg, J. J. M.
    Bogers, A. J. J. C.
    ANNALS OF THORACIC SURGERY, 2015, 100 (05): : 1968 - 1968
  • [7] Results of Hypofractionated Carbon-Ion Radiation Therapy for Peripherally Located Stage I Non-Small-Cell Lung Cancer
    Shioyama, Y.
    Terashima, K.
    Suefuji, H.
    Shinoto, M.
    Toyama, S.
    Matsumoto, K.
    Matsunobu, A.
    Oshima, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E706 - E706
  • [8] Multi-institutional Retrospective Study of Carbon Ion Radiation Therapy for Stage I Non-Small Cell Lung Cancer: Japan Carbon Ion Radiation Oncology Study Group
    Shioyama, Y.
    Yamamoto, N.
    Saitoh, J. I.
    Fujii, O.
    Matsunobu, A.
    Ohno, T.
    Okimoto, T.
    Tsuji, H.
    Kamada, T.
    Nakano, T.
    Nemoto, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S10 - S10
  • [9] Radiation Therapy for Stage I Nonoperable or Medically Inoperable Lung Cancer
    Kishan, Amar U.
    Lee, Percy
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 37 (05) : 716 - 726
  • [10] Stereotactic Body Radiation Therapy in Octogenarians With Stage I Lung Cancer
    Sandhu, Ajay P.
    Lau, Steven K. M.
    Rahn, Douglas
    Nath, Sameer K.
    Kim, Daniel
    Song, William Y.
    Gulaya, Sachin
    Fuster, Mark M.
    Bazhenova, Lyudmila
    Mundt, Arno J.
    CLINICAL LUNG CANCER, 2014, 15 (02) : 131 - 135